Who Optimizes SG&A Costs Better? Amgen Inc. or Zoetis Inc.

Optimizing SG&A Costs: Amgen Inc. vs. Zoetis Inc.

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Amgen Inc. and Zoetis Inc. have demonstrated distinct strategies in optimizing these costs. From 2014 to 2023, Amgen's SG&A expenses have seen a steady increase, peaking at approximately $6.2 billion in 2023, reflecting a 31% rise from 2014. In contrast, Zoetis Inc. has maintained a more conservative growth in SG&A expenses, with a 31% increase over the same period, reaching around $2.2 billion in 2023. This comparison highlights Amgen's aggressive expansion strategy, while Zoetis focuses on cost efficiency. Understanding these trends provides valuable insights into each company's operational priorities and financial health, offering investors a clearer picture of their strategic directions.